Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMM-1-104 |
| Synonyms | |
| Therapy Description |
IMM-1-104 inhibits MEK1 and MEK2, resulting in decreased downstream ERK1/2 activation and potentially leading to inhibition of tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P252). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMM-1-104 | IMM 1-104|IMM1-104 | MEK inhibitor (Pan) 27 MEK1 Inhibitor 27 MEK2 Inhibitor 25 | IMM-1-104 inhibits MEK1 and MEK2, resulting in decreased downstream ERK1/2 activation and potentially leading to inhibition of tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P252). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | melanoma | predicted - sensitive | IMM-1-104 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMM-1-104 treatment led to tumor growth inhibition in a cell line xenograft model of melanoma harboring BRAF V600E (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P252). | detail... |
| NRAS Q61R | melanoma | predicted - sensitive | IMM-1-104 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMM-1-104 treatment led to tumor growth regression in a cell line xenograft model of melanoma harboring NRAS Q61R (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P252). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05585320 | Phase Ib/II | IMM-1-104 Dabrafenib + IMM-1-104 IMM-1-104 + Pembrolizumab Gemcitabine + IMM-1-104 + Nab-paclitaxel Fluorouracil + IMM-1-104 + Irinotecan + Leucovorin + Oxaliplatin | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |